Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4451)	8/10/2001 4:22:59 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Point taken. I'm reminded of the fact that some beta blockers that don't cross the blood brain barrier (like atenolol) are effective in migraine prophylaxis. Peter

To: scaram(o)uche who wrote (4451)	8/10/2001 8:11:55 PM
From: Miljenko Zuanic	Respond to of 52153

<<I wouldn't assume that peripheral admin of an anti-TNF won't be effective for inflammatory disease in the brain.>> Maybe the better way looking on this issue is from safety-efficacy perspective. Because many (if not all) bio/chem candidates which are intended to treat damaged neurons (also degenerative disorders) who does cross BBB do much more harm that help, the issue is will anti-inflammatory candidates bring sufficient benefit without compromising safety. For instance in stroke? Because none can prevent/protect neurons damage from primary toxic chemicals in brain, can inflammatory protection (secondary destruction) be quantified as medical benefit? None have evidence that it can, but MLNM and many pharmas are betting on this. Miljenko